Monomethyl auristatin E (MMAE)

For research use only. Not for use in humans.

目录号:S7721 别名: SGD-1010 中文名称:一甲基澳瑞他汀E

Monomethyl auristatin E (MMAE) Chemical Structure

CAS No. 474645-27-7

Monomethyl auristatin E (MMAE, SGD-1010)是合成的抗肿瘤药,其与单克隆抗体(MAB)有关。它也是一种能够破坏微管的试剂。

规格 价格 库存 购买数量  
RMB 956.03 现货
RMB 2264.09 现货
RMB 6534.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Monomethyl auristatin E (MMAE)发表文献3篇:

产品安全说明书

ADC Cytotoxin抑制剂选择性比较

生物活性

产品描述 Monomethyl auristatin E (MMAE, SGD-1010)是合成的抗肿瘤药,其与单克隆抗体(MAB)有关。它也是一种能够破坏微管的试剂。
体外研究

耦合到cAC10时,MMAE在CD30+细胞中表现出选择性细胞毒性,并通过诱导细胞凋亡,引起G2/M期生长阻滞和细胞死亡。[1]在体外,与抗-CD79b抗体耦合时,抗-CD79b-vcMMAE对一大组NHL细胞系具有非常有效且广泛的活性。[2]与抗-HER2抗体耦合时,hertuzumab-vc-MMAE能够被充分吸收,并有效杀死HER2过表达的肿瘤细胞。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KB NE\WTJRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4\UdVQh\GG7cx?= NGPydXlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGy|IHHmeIVzKDRiZHH5d{BjgSC[VGSgZZN{[XluIFnDOVA:OC5yMECxPe69VQ>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NUe0N{c,OjN6NEW3OFM9N2F-
BT-12 NEHLN4ZyUFSVIHHzd4F6 M{\pTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MoLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEW3OFMoRjJ|OES1O|Q{RC:jPh?=
A549 Mn;ZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWK0JIRigXN? NFrmcphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IGjUWEBie3OjeTygTWM2OD1yLkCwNFU6|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NUe0N{c,OjN6NEW3OFM9N2F-
non-small cell lung cancer cells Mn7FR5l1d3SxeHnjbZR6KGG|c3H5 NVmzOFB2OC53IITvJFEhdk1? NIG0N481KGSjeYO= NICxenFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwh[2WubDDseY5oKGOjbnPldkBk\WyuczDheEAxNjVidH:gNUBvVSCjZoTldkA1KGSjeYOgZpkhYFSWIHHzd4F6 M3zNSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES1O|Q{Lz5{M{i0OVc1OzxxYU6=
A673 MWjxTHRUKGG|c3H5 MoDhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|MUi1PEc,OjV2M{G4OVg9N2F-
MDA-MB-361 NH\iNndEgXSxdH;4bYNqfHliYYPzZZk> M4OyXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2zOlEh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZwemViNDDkZZl{KGK7IF3UV{Bie3OjeTygS2k2OD1yLkCwNFQ6|ryP NXSyRXpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|E5PThpPkK1OFMyQDV6PD;hQi=>
NCI-N87 NF73[ItEgXSxdH;4bYNqfHliYYPzZZk> M2PP[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2QOEegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliaX7jeYJifGWmIH\vdoUhPCCmYYnzJIJ6KE2WUzDhd5NigSxiR1m1NF0xNjByMEW0{txO M3SzWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxPFU5Lz5{NUSzNVg2QDxxYU6=
OHS-50 NGfGRlFyUFSVIHHzd4F6 NHPZepNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUK3O{c,Ojh{MUGyO|c9N2F-
DU145 NFWwVXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzZeohQPDhiaILz M{HjeWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2wMlAxODRzON88US=> MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MUGyO|coRjJ6MkGxNlc4RC:jPh?=
SF268 M4jsRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX[0PEBpenN? NWK3VZFsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{NkigZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODByNEOy{txO NYLsSYx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVEzPzdpPkK4NlEyOjd5PD;hQi=>
KM20L2 NVXBSmJXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\pXo5sPDhiaILz MlT3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20zOEx{IHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2wMlAxODV7Od88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUK3O{c,Ojh{MUGyO|c9N2F-
NCI-H460 NWXCO|BJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2XCe|Q5KGi{cx?= M3\uO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0xNjByME[4N:69VQ>? NFLGOoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKxNVI4Pyd-MkiyNVEzPzd:L3G+
HCT116 NEPzOoJHfW6ldHnvckBie3OjeR?= MnvTNE42KG2P M{[xT|I1KGi{cx?= M37UNGVn\mWldDDvckBucXSxY3jvcoRzcWGuIILld5BqemG2aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG|ZTC5JIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDvfJlo\W5iY3;ud5VueHSrb36gdoF1\SCjdDCwMlUhdU1iYX\0[ZIhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NVK0WJpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PVU{QTRpPkK4PFk2Ozl2PD;hQi=>
DU145 NFPtN3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn6zOFghcHK| M1T1bGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB2MUlOwG0> M2nWb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEm1N|k1Lz5{OEi5OVM6PDxxYU6=
SF268 NYHlUVN{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjMOFghcHK| M1LuSGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNHOjZ6IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB2M{NOwG0> NFnnWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi5OVM6PCd-Mki4PVU{QTR:L3G+
KM20L2 NUSyVI1tT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXW0PEBpenN? NWDCNmJbT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU01{MFyyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1PVnPxE1? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh7NUO5OEc,Ojh6OUWzPVQ9N2F-
NCI-H460 NXe4dnhwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo\IOFghcHK| MkLuS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByME[4N:69VQ>? NU\QPWd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PVU{QTRpPkK4PFk2Ozl2PD;hQi=>
MCF7 NE\Vb2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlTkOFghcHK| MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1ODUQvF2= NH7aS489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1OCd-Mki5NlYzPDB:L3G+
DU145 M{TISGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHTUIsxPDhiaILz MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPDF6zszN MkTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFAoRjJ6OUK2NlQxRC:jPh?=
SF268 MlroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfDfGRUPDhiaILz MU\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTSlI3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPDN{zszN NH7jN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1OCd-Mki5NlYzPDB:L3G+
KM20L2 MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXq0PEBpenN? M{WyO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtOOjCOMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNUm5{txO MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl{NkK0NEc,Ojh7Mk[yOFA9N2F-
NCI-H460 NGL2WYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzsOFghcHK| Ml3PS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByME[4N:69VQ>? NGPuNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1OCd-Mki5NlYzPDB:L3G+
DAOY MmLpdWhVWyCjc4PhfS=> MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NYm5T49WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5O|I4PTVpPkK4PVczPzV3PD;hQi=>
A549 MkHNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHL6NIM4OiCqcoO= Mlu2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFXDOVA:OC5yMEC1{txO MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7N{K3OVUoRjJ6OUeyO|U2RC:jPh?=
SKOV3 MWDDfZRwfG:6aXPpeJkh[XO|YYm= M164OFIh\GG7cx?= MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{Bi\nSncjCyJIRigXNiYomgZ4VtdCC2aYTldkA6PiCjcYXlc5V{KG:wZTDzc4x2fGmxbjDiZZNm\CCjc4PhfUwhUUN3ME2wMlAxODZ4zszN NUjic2Y{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVQ4ODNpPkK5OFU1PzB|PD;hQi=>
A549 M{fiT2N6fG:2b4jpZ4l1gSCjc4PhfS=> Mo\xNkBl[Xm| NUntVldGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkAzKGSjeYOgZpkh[2WubDD0bZRmeiB7NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBj[XOnZDDhd5NigSxiSVO1NF0xNjByMUROwG0> NEDmd209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OFcxOyd-Mkm0OVQ4ODN:L3G+
L1210 M{W2VmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGntdFMzKGSjeYO= NIG3dZJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjZoTldkAzKGSjeYOgZpkh[2WubDD0bZRmeiB7NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBj[XOnZDDhd5NigSxiSVO1NF0xNjByMkJOwG0> MnvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUS3NFMoRjJ7NEW0O|A{RC:jPh?=
NCI-H524 MnfCR5l1d3SxeHnjbZR6KGG|c3H5 NHmwdJgzKGi{cx?= M3nyTmN6fG:2b4jpZ4l1gSCrbjDoeY1idiCQQ1mtTFUzPCClZXzsd{BxemVvaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqIH;1eEBidmRic4Xid4VyfWWwdHz5JIlv[3WkYYTl[EBnd3JiN{CgbJJ{KGK7IFPlcIwhXGm2ZYKgS4xwKGG|c3H5MEBKSzVyPUCuNFA{P87:TR?= M1\VN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyN{O1N|g2Lz5|MEezOVM5PTxxYU6=

... Click to View More Cell Line Experimental Data

体内研究 在Karpas 299 ALCL模型中,cAC10-vcMMAE (1 mg/kg, i.v.)诱导完全的,持久的肿瘤退化,而游离MMAE (0.36 mg/kg)不会产生可检测的抗肿瘤活性。[1]在NHL小鼠异种移植模型中,抗-CD79b-vcMMAE (7 mg/kg, p.o.)显著导致持续完全的肿瘤消退。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: CD30+ Karpas 299细胞
  • Concentrations: ~1000 ng/mL
  • Incubation Time: 96小时
  • Method:

    细胞毒性使用Alamar Blue染料还原试验根据制造商指示测量。简而言之,培养物加入之前,Alamar Blue 40% 的溶液(wt/vol)在完全培养基中新鲜制备。药物暴露92小时后,Alamar Blue加入到细胞中,构成10%的培养体积。细胞培养4小时,染料的减少在Fusion HT荧光分析仪(Packard仪器,Meriden,CT)上测量。


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (139.27 mM)
Water Insoluble
Ethanol '100 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 717.98
化学式
C39H67N5O7
 
CAS号 474645-27-7
储存条件 粉状
溶于溶剂
别名 SGD-1010

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04492488 Recruiting Drug: MRG002 Advanced Solid Tumors|Advanced or Metastatic Gastric Cancer|Advanced or Metastatic Gastroesophageal Junction Cancer Shanghai Miracogen Inc. May 24 2021 Phase 1|Phase 2
NCT04868162 Recruiting Drug: MRG003 Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Shanghai Miracogen Inc. April 23 2021 Phase 2
NCT04617314 Recruiting Drug: RC108 Solid Tumor RemeGen Co. Ltd. March 10 2021 Phase 1
NCT04561362 Recruiting Drug: BT8009|Drug: Nivolumab Advanced Solid Tumor|Urinary Bladder Neoplasm|Pancreatic Neoplasms|Triple Negative Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Stomach Neoplasm|Esophageal Neoplasms|Ovarian Neoplasm Bicycle Tx Limited July 17 2020 Phase 1|Phase 2
NCT04175847 Recruiting Drug: RC88 Solid Tumor RemeGen Co. Ltd. April 14 2020 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂
Tags: 购买Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE)供应商 | 采购Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE)价格 | Monomethyl auristatin E (MMAE)生产 | 订购Monomethyl auristatin E (MMAE) | Monomethyl auristatin E (MMAE)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID